morpholinoanthracycline mx2 has been researched along with carubicin in 51 studies
| Studies (morpholinoanthracycline mx2) | Trials (morpholinoanthracycline mx2) | Recent Studies (post-2010) (morpholinoanthracycline mx2) | Studies (carubicin) | Trials (carubicin) | Recent Studies (post-2010) (carubicin) |
|---|---|---|---|---|---|
| 53 | 15 | 0 | 340 | 40 | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (13.73) | 18.7374 |
| 1990's | 39 (76.47) | 18.2507 |
| 2000's | 5 (9.80) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kimura, I; Kiura, K; Ohnoshi, T; Takigawa, N; Ueoka, H | 1 |
| Fujiwara, Y; Kasahara, K; Kubo, S; Niitani, H; Nishio, K; Saijo, N; Sugimoto, Y; Takeda, Y | 1 |
| Majima, H; Shinkai, H | 1 |
| Eddy, L; Hochstein, P; Sato, Y | 1 |
| Kawai, H; Kikuchi, K; Otake, N; Shinkai, H; Takahashi, H | 1 |
| Isoe, T; Komeshima, N; Naito, M; Otake, N; Tsuruo, T; Watanabe, M | 1 |
| Arita, N; Hayakawa, T; Hiraga, S; Izumoto, S; Ohnishi, T; Taki, T; Yamamoto, H | 1 |
| Abe, O; Asanuma, F; Ishibiki, K; Josui, K; Kawamura, E; Koh, J; Kubota, T; Shiina, E; Suto, A; Yamada, Y | 1 |
| Bungo, M; Fourcade, A; Horichi, N; Kasahara, K; Lampidis, TJ; Nishiyama, M; Sasaki, Y; Sugimoto, Y; Takahashi, T; Tapiero, H | 1 |
| Majima, H | 1 |
| Bungo, M; Fujiwara, Y; Fukuda, M; Horichi, N; Minato, K; Nakagawa, K; Niimi, S; Ohe, Y; Saijo, N; Sasaki, Y | 1 |
| Fukutani, H; Hirano, A; Horikoshi, N; Inoue, K; Mizunuma, N; Mukaiyama, T; Nagamine, D; Ogawa, M; Shinagawa, K; Tabata, M | 1 |
| Kawai, H; Komeshima, N; Nakajima, S; Otake, N; Takeuchi, T; Tsuruo, T; Watanabe, M | 1 |
| Kochi, M; Kuratsu, J; Mihara, Y; Takaki, S; Ushio, Y | 1 |
| Komeshima, N; Nakajima, S; Tsuruo, T; Watanabe, M | 1 |
| Arita, N; Hayakawa, T; Izumoto, S; Komeshima, N; Mogami, H; Ohnishi, T; Oku, Y; Taki, T; Ushio, Y; Yamamoto, H | 1 |
| Kawai, H; Komeshima, N; Nakajima, S; Odagawa, A; Otake, N; Otsuki, N; Tatsuta, K; Umezawa, H; Urata, T; Yoshimoto, H | 1 |
| Kabuto, M; Kitai, R; Kobayashi, H; Kubota, T; Nakagawa, T | 1 |
| Kabuto, M; Kitai, R; Kobayashi, H; Kodera, T; Kubota, T; Nakagawa, T; Uno, H | 1 |
| Kaoru, K; Katsuzo, K; Tohru, U; Yasunori, K; Yuki, K | 1 |
| Lampidis, TJ; Nguyen-Ba, G; Tapiero, H | 1 |
| Fukue, H; Fukutake, K; Gohchi, K; Ishigatsubo, Y; Kimura, S; Koitabashi, Y; Matsuda, J; Okubo, T; Shimada, K; Yamada, K | 1 |
| Arai, Y; Kabuto, M; Kitai, R; Kobayashi, H; Kubota, T; Nakagawa, T | 1 |
| Ohnishi, K; Ohno, R | 1 |
| Arita, N; Hayakawa, T; Higuchi, M; Hiraga, S; Izumoto, S; Ohnishi, T; Shinkai, H; Taki, T; Yamamoto, H | 1 |
| Abe, O; Adachi, I; Enomoto, K; Haga, S; Kawamura, E; Kimura, K; Kusama, M; Narabayashi, M; Watanabe, T; Yamada, Y | 1 |
| Ariyoshi, Y; Ogawa, M | 1 |
| Fujita, H; Kawamoto, K; Kiya, K; Kurisu, K; Ogasawara, H; Shinkai, H; Sugiyama, K; Uozumi, T | 1 |
| Clark, GM; Ebrahim el-Zayat, AA; Izquierdo, MA; Von Hoff, DD | 1 |
| Bämmler, TK; Duran, GE; Kühl, JS; Lau, DH; Lewis, AD; Sikic, BI | 1 |
| Miyamoto, K; Shinkai, H; Takahashi, H; Tokiwa, T; Uchida, T | 1 |
| Basser, RL; Cebon, J; Clarke, K; Geldard, H; Green, MD; Hill, JS; Kaye, AH; Maher, DW; Morgan, DJ; Park, SJ; Stylli, SS | 2 |
| Adachi, M; Date, M; Fukuhara, S; Katsurada, T; Kido, H; Kimura, T; Kishimoto, Y; Yamanaka, Y | 1 |
| Cosolo, W; Zalcberg, J; Zhang, WZ | 1 |
| Alt, C; Bartlett, J; Basser, RL; Cebon, J; Clarke, K; Fox, RM; Geldard, H; Green, MD; Hill, JS; Kaye, AH; Maher, D; Morgan, DJ | 1 |
| Kuraishi, Y; Ogawa, M; Okabe, K; Sampi, K; Takemoto, Y; Tamura, K | 1 |
| Kuraishi, Y; Ogawa, M; Sampi, K; Takemoto, Y; Tamura, K; Toki, H | 1 |
| Hiraoka, A; Kuraishi, Y; Ogawa, M; Okabe, K; Sampi, K; Takemoto, Y; Tamura, K | 1 |
| Hu, XF; Kantharidis, P; Parkin, JD; Rischin, D; Slater, A; Zalcberg, J | 1 |
| Abe, O; Adachi, I; Enomoto, K; Kajiwara, T; Katsumata, N; Kusama, M; Ogawa, M; Tominaga, T; Watanabe, T; Yamada, Y | 1 |
| Kishimoto, Y; Kuraishi, Y; Masaoka, T; Mizoguchi, H; Ogawa, M; Okabe, K; Saito, H; Sampi, K; Takemoto, Y; Tamura, K | 1 |
| Furuta, T; Matsumoto, K; Mizumatsu, S; Ohmoto, T; Ono, Y; Tamiya, T | 2 |
| Arita, N; Hayakawa, T; Kuratsu, J; Kurisu, K; Uozumi, T; Ushio, Y | 1 |
| Kuraishi, Y; Masaoka, T; Mizoguchi, H; Ogawa, M; Okabe, K; Saito, H; Sampi, K; Takemoto, Y; Tamura, K | 1 |
| Bartlett, J; Basser, RL; Byrne, M; Cher, L; Clarke, K; Dalley, D; Findlay, M; Fox, RM; Geldard, H; Green, MD; Hill, JS; Kaye, AH; Maher, D; Mitchell, P; Pell, M; Underhill, C | 1 |
| Hill, JS; Kaye, AH; Park, SJ | 1 |
| Arita, N; Kayama, T; Kubo, N; Kuratsu, JI; Mori, T; Sawamura, Y; Ushio, Y | 1 |
| Mima, T; Mori, K; Mostafa, MG | 1 |
| Adachi, M; Asano, T; Fujii, H; Fukunaga, Y; Hasegawa, K; Horichi, N; Isoe, T; Nakamura, K; Ohmori, T; Otake, N | 1 |
2 review(s) available for morpholinoanthracycline mx2 and carubicin
| Article | Year |
|---|---|
[New antitumor drugs for malignant lymphoma: a review].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carubicin; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Piperazines | 1994 |
[New anthracyclines].
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Carubicin; Doxorubicin; Humans; Idarubicin; Leukemia, Experimental; Leukemia, Myeloid, Acute; Menogaril; Stomach Neoplasms | 1993 |
15 trial(s) available for morpholinoanthracycline mx2 and carubicin
| Article | Year |
|---|---|
[Phase III clinical trial of KRN8601 (rhG-CSF) for neutropenia in patients with human immunodeficiency virus infection].
Topics: Adolescent; Adult; Carubicin; Female; HIV Infections; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia | 1994 |
MX2; 3'-deamino-3'-morpholino-13-deoxy-10-hydroxycarminomycin (KRN8602) in refractory metastatic breast cancer: results of a preliminary phase II trial.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Carubicin; Female; Humans; Middle Aged | 1993 |
[New anthracyclines].
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Carubicin; Doxorubicin; Humans; Idarubicin; Leukemia, Experimental; Leukemia, Myeloid, Acute; Menogaril; Stomach Neoplasms | 1993 |
Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Area Under Curve; Carubicin; Doxorubicin; Female; Half-Life; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Neutropenia; Neutrophils; Safety | 1997 |
Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease.
Topics: Antibiotics, Antineoplastic; Area Under Curve; Carubicin; Dose-Response Relationship, Drug; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Metabolic Clearance Rate; Neoplasms; Neutrophils; Recombinant Proteins | 1998 |
Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carubicin; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Recombinant Proteins; Treatment Outcome | 1998 |
[Phase II study of KRN8602 (MX2) for malignant lymphoma].
Topics: Anorexia; Antibiotics, Antineoplastic; Carubicin; Drug Administration Schedule; Hodgkin Disease; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Nausea; Thrombocytopenia; Vomiting | 1998 |
[Early phase II study of KRN8602 (MX2), a novel anthracycline derivative for acute leukemia].
Topics: Adult; Aged; Anorexia; Antibiotics, Antineoplastic; Carubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vomiting | 1998 |
[Pilot late phase II study of KRN8602 (MX2), a novel anthracycline derivative, for acute leukemia--a dose finding study in combination].
Topics: Adult; Aged; Anorexia; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carubicin; Cytarabine; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Vincristine; Vomiting, Anticipatory | 1999 |
Phase II study of KRN8602, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin hydrochloride, MX2 x HCl in patients with metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Carubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis | 1999 |
A phase II study employing combination regimens containing KRN8602 in drug-resistant acute myeloid leukemia and acute lymphoblastic leukemia. KRN8602 Leukemia Study Group.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carubicin; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Treatment Failure; Vincristine | 1999 |
A phase II study of KRN8602(MX2), a novel morpholino anthracycline derivative, in patients with recurrent malignant glioma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Brain Neoplasms; Carubicin; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local | 1999 |
A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carubicin; Central Nervous System Diseases; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Treatment Outcome | 1999 |
KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Astrocytoma; Brain Neoplasms; Carubicin; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Survival Analysis | 1999 |
Phase II trial of pre-irradiation KRN8602 (MX2) in malignant glioma patients.
Topics: Adult; Antibiotics, Antineoplastic; Astrocytoma; Brain Neoplasms; Cardiomyopathies; Carubicin; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Glioblastoma; Humans; Leukopenia; Male; Middle Aged; Nausea; Oligodendroglioma; Treatment Outcome; Vomiting | 2000 |
35 other study(ies) available for morpholinoanthracycline mx2 and carubicin
| Article | Year |
|---|---|
Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Carubicin; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Molecular Structure; Tumor Cells, Cultured | 1992 |
Establishment of a human leukemia subline resistant to the growth-inhibitory effect of 12-O-tetradecanoylphorbol 13-acetate (TPA) and showing non-P-glycoprotein-mediated multi-drug resistance.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carubicin; Cell Division; Cell Line; Cell Survival; Doxorubicin; Drug Resistance; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Glycoproteins; Subcellular Fractions; Tetradecanoylphorbol Acetate | 1991 |
[Pharmacokinetics of KRN 8602 in cancer patients].
Topics: Adult; Antibiotics, Antineoplastic; Breast Neoplasms; Carubicin; Drug Evaluation; Female; Humans; Infusions, Intravenous; Middle Aged | 1991 |
Comparative cardiotoxicity of doxorubicin and a morpholino anthracycline derivative (KRN8602).
Topics: Animals; Carubicin; Doxorubicin; Glutathione; Heart Diseases; Lipid Peroxidation; Male; Microsomes, Liver; Perfusion; Rats; Rats, Inbred Strains | 1991 |
Determination of the new morpholino anthracycline MX2.HCl and its metabolites in biological samples by high-performance liquid chromatography.
Topics: Animals; Antibiotics, Antineoplastic; Carubicin; Chromatography, High Pressure Liquid; Rats; Spectrometry, Fluorescence | 1991 |
Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells.
Topics: Antibiotics, Antineoplastic; Binding Sites; Carubicin; Cell Division; Cell Membrane; Cell Survival; Drug Resistance; Growth Inhibitors; Humans; In Vitro Techniques; Tumor Cells, Cultured; Verapamil; Vincristine | 1991 |
[Distribution and acute toxicity of a new morpholinoanthracycline, MX2, in normal rat brain after intra-arterial injection].
Topics: Animals; Antibiotics, Antineoplastic; Brain; Carubicin; Female; Injections, Intra-Arterial; Injections, Intravenous; Rats; Rats, Inbred Strains | 1991 |
Antitumor activity and pharmacokinetics of a morpholino-anthracycline derivative (KRN8602) against human breast carcinoma xenografts serially transplanted into nude mice.
Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Carubicin; Daunorubicin; Drug Administration Schedule; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Specific Pathogen-Free Organisms | 1990 |
3'-Deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks.
Topics: Antibiotics, Antineoplastic; Biological Transport; Carubicin; Cell Line; Cell Nucleus; Cell Survival; Daunorubicin; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; DNA, Single-Stranded; Doxorubicin; Drug Resistance; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Tumor Cells, Cultured | 1990 |
[Phase I clinical study of MX2 (KRN 8602)].
Topics: Adult; Antibiotics, Antineoplastic; Breast Neoplasms; Carubicin; Daunorubicin; Drug Evaluation; Female; Humans; Injections, Intravenous; Leukopenia; Male; Middle Aged; Nausea; Stomach Neoplasms; Vomiting | 1990 |
In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Carubicin; Cisplatin; Daunorubicin; Doxorubicin; Drug Resistance; Humans; Menogaril; Mitomycins; Nogalamycin; Tumor Cells, Cultured | 1989 |
[Phase I and pharmacokinetic study of KRN8602, a new morpholino anthracycline].
Topics: Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carubicin; Drug Evaluation; Female; Hodgkin Disease; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia | 1989 |
Role of DNA-binding in the cytotoxicity of an anthracycline, R20X2 and its morpholino analog, MX2.
Topics: Animals; Carubicin; Cells, Cultured; Daunorubicin; DNA, Neoplasm; Leukemia P388; Leukemia, Experimental; Rats; Structure-Activity Relationship | 1989 |
[Antitumor effect of a new anthracycline derivative, MX2, against human glioma cells].
Topics: Animals; Antibiotics, Antineoplastic; Carubicin; Cell Line; Doxorubicin; Glioma; Humans; In Vitro Techniques; Mice; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous; Tumor Cells, Cultured | 1989 |
MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
Topics: Animals; Antibiotics, Antineoplastic; Carubicin; Doxorubicin; Drug Resistance; Humans; Leukemia L1210; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Neoplasms, Experimental; Transplantation, Heterologous; Tumor Cells, Cultured | 1988 |
[Effect of MX-2, a morpholino anthracycline derivative, against human and rat glioma cells and experimental leptomeningeal tumors in rats].
Topics: Animals; Antibiotics, Antineoplastic; Arachnoid; Brain Neoplasms; Carubicin; Female; Glioma; Humans; Meningeal Neoplasms; Naphthacenes; Pia Mater; Rats; Rats, Inbred Strains | 1988 |
New morpholino anthracyclines, MX, MX2, and MY5.
Topics: Animals; Anthracyclines; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Carubicin; Leukemia P388; Mice; Naphthacenes | 1987 |
The antitumor effect of MX2, a new morpholino anthracycline, against malignant glioma cell lines and its subcellular distribution.
Topics: Animals; Antibiotics, Antineoplastic; Brain; Brain Neoplasms; Carubicin; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Glioma; Humans; Male; Microscopy, Electron; Neoplasm Transplantation; Rats; Rats, Wistar; Subcellular Fractions; Tissue Distribution; Tumor Cells, Cultured | 1995 |
[Antitumor effect of MX2, a new morpholino anthracycline against C6 glioma cells and its combination effect with photodynamic therapy in vitro].
Topics: Animals; Antibiotics, Antineoplastic; Carubicin; Glioma; Photochemotherapy; Rats; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1995 |
[Antitumor effect of KRN 8602 for malignant brain tumors using collagen gel matrix assay].
Topics: Animals; Antibiotics, Antineoplastic; Brain Neoplasms; Carubicin; Collagen; Drug Screening Assays, Antitumor; Gels; Glioblastoma; Humans; Medulloblastoma; Mice; Neoplasm Transplantation; Tumor Cells, Cultured | 1995 |
Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
Topics: Aclarubicin; Animals; Carubicin; Cells, Cultured; Daunorubicin; DNA, Neoplasm; Doxorubicin; Drug Resistance; Humans; In Vitro Techniques; Mice; Tumor Cells, Cultured; Verapamil | 1994 |
Subcellular localization and cellular pharmacokinetics of MX2, a new morpholino anthracycline in glioma cells using confocal laser scanning microscopy.
Topics: Animals; Antibiotics, Antineoplastic; Biological Transport; Carubicin; Cell Line; Doxorubicin; Glioma; Humans; Male; Microscopy, Confocal; Microscopy, Electron; Rats; Rats, Wistar; Subcellular Fractions; Time Factors | 1994 |
[Pharmacokinetics of MX2, a new morpholino anthracycline, in CSF following intravenous injection].
Topics: Animals; Antibiotics, Antineoplastic; Blood-Brain Barrier; Brain; Carubicin; Injections, Intravenous; Rabbits | 1993 |
[Pharmacokinetics and antitumor activity of MX2, a new morpholino anthracycline in brain tumor intracerebral transplanted in rats].
Topics: Animals; Antibiotics, Antineoplastic; Brain; Brain Neoplasms; Carubicin; Cell Division; Female; Glioma; Neoplasm Transplantation; Rats; Rats, Inbred F344; Tumor Cells, Cultured | 1993 |
Activity of the morpholino anthracycline 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin (MX2) against human tumor colony-forming units in vitro.
Topics: Antibiotics, Antineoplastic; Carubicin; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drugs, Investigational; Humans; Neoplasms; Neoplastic Stem Cells; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1995 |
Differential single- versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues.
Topics: Antibiotics, Antineoplastic; Carcinoma; Carubicin; DNA; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; DNA, Single-Stranded; Doxorubicin; Electrophoresis, Agar Gel; Electrophoresis, Gel, Pulsed-Field; Female; Humans; Ovarian Neoplasms; Tumor Cells, Cultured | 1996 |
Comparative pharmacokinetics of KRN8602, a new morpholino anthracycline, and adriamycin in tumor-bearing mice.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Brain Chemistry; Carubicin; Cell Survival; Chromatography, High Pressure Liquid; Colonic Neoplasms; Doxorubicin; Female; Intestine, Small; Kidney; Leukemia P388; Liver; Lung; Mice; Myocardium; Neoplasm Transplantation; Spleen; Tissue Distribution; Tumor Cells, Cultured | 1996 |
Induction of apoptosis in megakaryocytic leukemia cell lines by MX2, a morpholino anthracycline.
Topics: Antibiotics, Antineoplastic; Apoptosis; Benzoquinones; Carubicin; DNA Fragmentation; Enzyme Inhibitors; Humans; Ionomycin; Lactams, Macrocyclic; Leukemia, Megakaryoblastic, Acute; Megakaryocytes; Microscopy, Electron; Protein-Tyrosine Kinases; Quinones; Rifabutin; Staurosporine; Tumor Cells, Cultured | 1997 |
In vitro binding of MX2 (KRN8602) and epirubicin to human plasma protein.
Topics: Antibiotics, Antineoplastic; Blood Proteins; Carubicin; Epirubicin; Humans; In Vitro Techniques; Protein Binding | 1997 |
Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line.
Topics: Anthracyclines; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carubicin; Cell Survival; Clone Cells; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Gene Expression Regulation, Neoplastic; Humans; Idarubicin; Kinetics; Leukemia, T-Cell; Structure-Activity Relationship; Tumor Cells, Cultured | 1999 |
[Combination effect of hyperthermia and MX2 on cultured glioma cell lines].
Topics: Animals; Antibiotics, Antineoplastic; Carubicin; Cell Survival; Coloring Agents; Combined Modality Therapy; Culture Media; Glioma; Humans; Hyperthermia, Induced; Rats; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1999 |
An investigation of the cytotoxicity of the morpholino anthracycline MX2 against glioma cells in vitro.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Carubicin; Cell Division; Glioma; Humans; Lipoproteins; Rats; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |
Intrathecal chemotherapy with MX2 for treating glioma dissemination in vivo.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Carubicin; Dose-Response Relationship, Drug; Feasibility Studies; Glioma; Injections, Intraventricular; Injections, Spinal; Male; Nervous System Diseases; Rats; Rats, Wistar; Survival Analysis | 2000 |
Antitumor effect and peritumoral brain edema formation in relation to MX2, ACNU, and doxorubicin therapy: a comparative analysis using rodent models of gliomas.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Body Weight; Brain Edema; Brain Neoplasms; Carubicin; Disease Models, Animal; Doxorubicin; Glioma; Leukocyte Count; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Nimustine; Rats; Survival Rate | 2000 |
Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Azacitidine; Blotting, Northern; Carubicin; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; Humans; Immunoblotting; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |